Voting Rights and Shares Capital of the Company
Nanobiotix (NBTX) has issued a standard regulatory filing regarding its voting rights and share capital in compliance with French regulatory requirements. The announcement was made in accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the French Financial Markets Authority regulations.
The company's shares are listed on both Euronext Paris (Compartment B) and Nasdaq under the ticker symbol NBTX. The company's ISIN code is FR0011341205.
Nanobiotix (NBTX) ha emesso un documento di registrazione standard riguardante i suoi diritti di voto e il capitale sociale in conformità con i requisiti normativi francesi. L'annuncio è stato fatto in conformità agli articoli L.233-8 II del Codice Commerciale francese e 223-16 delle normative dell'Autorità dei Mercati Finanziari francese.
Le azioni della società sono quotate sia su Euronext Paris (Comparto B) che su Nasdaq con il simbolo ticker NBTX. Il codice ISIN della società è FR0011341205.
Nanobiotix (NBTX) ha emitido un documento de presentación estándar sobre sus derechos de voto y capital social, cumpliendo con los requisitos regulatorios franceses. El anuncio se realizó de acuerdo con los artículos L.233-8 II del Código de Comercio francés y 223-16 de las regulaciones de la Autoridad de Mercados Financieros de Francia.
Las acciones de la empresa están cotizadas tanto en Euronext París (Compartimento B) como en Nasdaq bajo el símbolo de cotización NBTX. El código ISIN de la empresa es FR0011341205.
Nanobiotix (NBTX)는 프랑스 규제 요건에 따라 투표권 및 자본금에 관한 표준 규제 서류를 발행했습니다. 이 발표는 프랑스 상법 제 L.233-8 II조 및 프랑스 금융 시장 당국 규정 제 223-16조에 따라 이루어졌습니다.
회사의 주식은 Euronext 파리 (부문 B)와 나스닥에 NBTX라는 티커 기호로 상장되어 있습니다. 회사의 ISIN 코드는 FR0011341205입니다.
Nanobiotix (NBTX) a publié un dossier réglementaire standard concernant ses droits de vote et son capital social, conformément aux exigences réglementaires françaises. L'annonce a été faite conformément aux articles L.233-8 II du Code de commerce français et 223-16 des règlements de l'Autorité des marchés financiers française.
Les actions de la société sont cotées à la fois sur Euronext Paris (Compartiment B) et sur Nasdaq sous le symbole boursier NBTX. Le code ISIN de la société est FR0011341205.
Nanobiotix (NBTX) hat eine standardmäßige regulatorische Einreichung bezüglich seiner Stimmrechte und seines Aktienkapitals gemäß den französischen Regulierungsanforderungen vorgenommen. Die Bekanntgabe erfolgte gemäß den Artikeln L.233-8 II des französischen Handelsgesetzbuchs und 223-16 der Vorschriften der französischen Finanzmarktaufsicht.
Die Aktien des Unternehmens sind sowohl an der Euronext Paris (Bereich B) als auch an der Nasdaq unter dem Tickersymbol NBTX notiert. Der ISIN-Code des Unternehmens lautet FR0011341205.
- None.
- None.
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
PARIS, March 13, 2025 (GLOBE NEWSWIRE) --
Paris, France, March 13, 2025
Market: Euronext Paris / Nasdaq
Euronext Compartment: B
ISIN code: FR0011341205
Nasdaq: NBTX
Bloomberg: NANO:FP
Reuters: NANO.PA
Website: www.nanobiotix.com
| Date | Number of Shares Outstanding | Total number of voting rights | |
| Total voting rights, theoretical1 | Total voting rights, exercisable2 | ||
| February 28, 2025 | 47,426,851 | 49,207,475 | 49,185,357 |
About NANOBIOTIX
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.
Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.
For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.
Contacts
| Nanobiotix | ||
| Communications Department Brandon Owens VP, Communications +1 (617) 852-4835 contact@nanobiotix.com | Investor Relations Department Craig West SVP, Investor Relations +1 (617) 583-0211 investors@nanobiotix.com | |
| Media Relations | ||
France – HARDY Caroline Hardy +33 06 70 33 49 50 carolinehardy@outlook.fr | Global – LifeSci Advisors Kevin Gardner +1 (617) 283-2856 kgardner@lifesciadvisors.com | |
____________________
1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.
2 The total number of exercisable at a shareholders’ meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed.
Attachment
FAQ
What regulatory requirements is NBTX fulfilling with this announcement?
On which exchanges are Nanobiotix (NBTX) shares traded?
What is the ISIN code for NBTX shares?
When did NBTX make this regulatory announcement?
